Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
|Articles|August 23, 2021
September billing & coding workshop
Author(s)Lauretta Justin, OD
Advertisement
Optometry Divas is excited to offer this much anticipated virtual workshop with internationally renowned Billing and Coding expert, Dr. John Rumpakis. In this workshop, attendees will learn coding and reimbursement tips for success along with pitfalls to avoid. To learn more about this upcoming event, visit
Advertisement
Related to this article
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.
Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.
Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances in Contact Lens Care for the New Contact Lens Technologies."
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
2
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
3
Missed AAOpt 2026? Here are the highlights by specialty
4
FDA approves subcutaneous Enspryng for TED
5